Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs

Question 171: Phase II drug metabolism reactions include all of the following EXCEPT:

A. Acetylation
B. Glycine conjugation
C. Methylation
D. Reduction (Correct Answer)

Explanation: Drug metabolism (biotransformation) typically occurs in two phases to make lipophilic drugs more polar for excretion. **Phase I Reactions (Functionalization):** These reactions introduce or expose a functional group (–OH, –NH2, –SH). They include **Oxidation** (most common, via CYP450), **Reduction**, and **Hydrolysis**. * **Reduction** is a Phase I reaction; therefore, it is the correct answer to the "EXCEPT" question. Examples of drugs undergoing reduction include Chloramphenicol and Halothane. **Phase II Reactions (Conjugation):** These involve the attachment of an endogenous group to the drug to form a highly polar, inactive metabolite. * **Acetylation (Option A):** A Phase II reaction mediated by N-acetyltransferase (NAT). Important for drugs like Isoniazid, Hydralazine, and Procainamide. * **Glycine Conjugation (Option B):** A Phase II reaction. A classic example is the conversion of Salicylic acid to Salicyluric acid. * **Methylation (Option C):** A Phase II reaction mediated by methyltransferases. Examples include the metabolism of Epinephrine and Dopamine. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Phase I:** **HOR** (Hydrolysis, Oxidation, Reduction). * **Mnemonic for Phase II:** **G**ASP **M**e (Glucuronidation, Acetylation, Sulfation, Phosphorylation, Methylation). * **Glucuronidation** is the most common Phase II reaction. * **Microsomal vs. Non-microsomal:** Most Phase I enzymes are microsomal (located in the SER), while most Phase II enzymes are non-microsomal (cytosolic), with the notable exception of **Glucuronosyltransferase**, which is microsomal. * **Gray Baby Syndrome:** Occurs in neonates due to deficient Glucuronidation of Chloramphenicol.

Question 172: Liposomes are used for drug delivery in all of the following except?

A. Amphotericin-B
B. Doxorubicin
C. Propranolol (Correct Answer)
D. Vincristine

Explanation: Liposomes are microscopic spherical vesicles composed of a phospholipid bilayer surrounding an aqueous core. They are used as **targeted drug delivery systems** to enhance the therapeutic index, reduce systemic toxicity, and improve the solubility of drugs. **Why Propranolol is the Correct Answer:** Propranolol is a highly lipophilic, non-selective beta-blocker with excellent oral bioavailability and predictable pharmacokinetics [2], [3]. It does not require a specialized delivery system like liposomes for its clinical application. Liposomal technology is typically reserved for drugs with **high systemic toxicity** [1] or those requiring **targeted delivery** to specific tissues (like tumors or fungal cells). **Analysis of Incorrect Options:** * **Amphotericin-B:** Conventional Amphotericin-B is highly nephrotoxic. Liposomal Amphotericin-B (L-AMB) is the gold standard for reducing renal toxicity while maintaining efficacy against systemic fungal infections [1], [1]. * **Doxorubicin:** This chemotherapeutic agent is notorious for dose-limiting cardiotoxicity. Liposomal formulation (Pegylated) ensures the drug remains in the circulation longer and preferentially extravasates into tumor tissues, significantly reducing cardiac damage. * **Vincristine:** Liposomal vincristine improves the pharmacokinetics of the drug, allowing for higher dose intensity and better penetration into lymphoid tissues while potentially reducing peripheral neuropathy. **High-Yield Clinical Pearls for NEET-PG:** * **Stealth Liposomes:** These are coated with **Polyethylene Glycol (PEG)** to avoid detection by the Reticuloendothelial System (RES), thereby increasing the drug's half-life. * **Targeting:** Liposomes are particularly useful for targeting the **Liver and Spleen** (as they are naturally taken up by macrophages). * **Other Liposomal Drugs:** Daunorubicin, Cytarabine, and Morphine (extended-release epidural).

Question 173: What is the first active metabolite of chloral hydrate?

A. Ethanol
B. Dichloroethanol
C. Trichloroethanol (Correct Answer)
D. Monochloroethanol

Explanation: **Explanation:** **Chloral hydrate** is a classic sedative-hypnotic prodrug. Its pharmacological activity is almost entirely due to its rapid conversion in the body. **1. Why Trichloroethanol is correct:** Upon ingestion, chloral hydrate is rapidly metabolized by the enzyme **alcohol dehydrogenase** (primarily in the liver and erythrocytes) into **trichloroethanol**. This metabolite is the active moiety responsible for the drug’s sedative and hypnotic effects. It acts similarly to benzodiazepines and barbiturates by enhancing the GABA-A receptor complex. Trichloroethanol is subsequently conjugated with glucuronic acid to form urochloralic acid, which is excreted in the urine. **2. Why the other options are incorrect:** * **Ethanol (A):** While ethanol and chloral hydrate interact (the "Mickey Finn" effect), ethanol is not a metabolite of chloral hydrate. Interestingly, ethanol acts as a cofactor that speeds up the conversion of chloral hydrate to trichloroethanol. * **Dichloroethanol (B) and Monochloroethanol (D):** These are not standard metabolic products of chloral hydrate. The chemical structure of chloral hydrate ($CCl_3CH(OH)_2$) specifically leads to the tri-chlorinated alcohol derivative. **3. High-Yield Clinical Pearls for NEET-PG:** * **The "Mickey Finn":** Combining chloral hydrate with alcohol significantly enhances CNS depression because ethanol increases the NADH/NAD ratio, accelerating the formation of the active trichloroethanol. * **Pear-like Odor:** Chloral hydrate is known for its characteristic pungent, pear-like (or fruity) odor and unpleasant taste. * **Radiology Use:** It was historically used for pediatric sedation during non-invasive procedures (like MRIs), though it has largely been replaced by safer agents due to its narrow therapeutic index and gastric irritation. * **Warfarin Interaction:** It can displace warfarin from plasma albumin, transiently increasing the anticoagulant effect.

Question 174: A new antifungal medication has a half-life of 6 hours. If a continuous intravenous infusion of this drug were started, how long would it take to reach 75% of steady state?

A. 3 hours
B. 6 hours
C. 9 hours
D. 12 hours (Correct Answer)

Explanation: ### Explanation The time required to reach a steady-state concentration ($C_{ss}$) during a continuous intravenous infusion is determined solely by the drug's **half-life ($t_{1/2}$)** [1]. It is independent of the dose or the rate of infusion. **The Rule of Half-Lives:** The accumulation of a drug toward steady state follows first-order kinetics [2]: * 1 Half-life $\rightarrow$ 50% of $C_{ss}$ * **2 Half-lives $\rightarrow$ 75% of $C_{ss}$** * 3 Half-lives $\rightarrow$ 87.5% of $C_{ss}$ * 4 to 5 Half-lives $\rightarrow$ >90% (Clinically considered steady state) In this question, the half-life is **6 hours**. To reach 75% of the steady state, the drug must pass through 2 half-lives. Calculation: $2 \times 6 \text{ hours} = \mathbf{12 \text{ hours}}$. --- ### Analysis of Options: * **A (3 hours):** This represents 0.5 half-lives; the drug concentration would be significantly below the therapeutic steady state. * **B (6 hours):** This is 1 half-life, at which point the drug reaches only 50% of its steady-state concentration. * **C (9 hours):** This is 1.5 half-lives, resulting in approximately 62.5% of $C_{ss}$. * **D (12 hours):** **Correct.** As calculated, 2 half-lives are required to reach 75% of $C_{ss}$. --- ### NEET-PG High-Yield Pearls: 1. **Steady State Principle:** It takes approximately **4–5 half-lives** to reach clinical steady state ($>93\%$) and the same amount of time to completely eliminate a drug from the body after stopping the infusion [1]. 2. **Loading Dose:** If a rapid therapeutic effect is needed (e.g., in emergencies), a **Loading Dose** is given to bypass the delay caused by the half-life [3]. It does not change the time to reach steady state but achieves the target concentration immediately. 3. **Formula:** $C_{ss} = \text{Infusion Rate} / \text{Clearance}$. Note that half-life is not in the formula for the *level* of $C_{ss}$, only the *time* to reach it [2].

Question 175: Loading dose is given for which of the following drugs?

A. Diazepam
B. Propranolol
C. Chloroquine (Correct Answer)
D. Aspirin

Explanation: **Explanation:** The correct answer is **Chloroquine**. **1. Why Chloroquine is correct:** The primary pharmacological reason for giving a loading dose is to rapidly achieve the **steady-state plasma concentration ($C_{ss}$)** for drugs with a **large volume of distribution ($V_d$)** or a **long half-life ($t_{1/2}$)**. Chloroquine has an exceptionally high $V_d$ (approx. 13,000 L) because it extensively binds to tissues (melanin in eyes, liver, and muscles). Without a loading dose, it would take weeks to reach therapeutic levels. In clinical practice (e.g., treating malaria), a loading dose of 600 mg base is given initially, followed by 300 mg to ensure immediate therapeutic efficacy against the parasite. **2. Why other options are incorrect:** * **Diazepam:** It is a lipid-soluble benzodiazepine with a relatively rapid onset. While it has a long half-life due to active metabolites, it does not require a loading dose for its standard sedative or anxiolytic effects. * **Propranolol:** It undergoes significant first-pass metabolism. Dosage is usually titrated based on heart rate and clinical response rather than a calculated loading dose. * **Aspirin:** Used primarily for its antiplatelet (low dose) or analgesic/anti-inflammatory effects. It has a short half-life and reaches effective concentrations quickly without a loading dose. **3. High-Yield Clinical Pearls for NEET-PG:** * **Formula:** $\text{Loading Dose} = \frac{V_d \times \text{Target } C_{p}}{\text{Bioavailability (F)}}$. * **Key Concept:** Loading dose depends on **Volume of Distribution**, whereas Maintenance Dose depends on **Clearance**. * **Other drugs requiring loading doses:** Amiodarone (very high $V_d$), Digoxin, Phenytoin, and Teicoplanin. * **Caution:** Loading doses carry a higher risk of toxicity; for example, rapid IV injection of a loading dose of Phenytoin or Aminophylline can cause cardiac arrhythmias.

Question 176: Urinary alkalization increases urine elimination of all the following drugs, except:

A. Salicylate
B. Methotrexate
C. Amphetamine (Correct Answer)
D. Phenobarbital

Explanation: ### Explanation The core principle behind this question is **Ion Trapping**, which is based on the **Henderson-Hasselbalch equation**. This concept dictates that a drug in its ionized (charged) form cannot easily cross lipid membranes and is therefore trapped in the renal tubules, leading to increased excretion. **1. Why Amphetamine is the Correct Answer:** Amphetamine is a **weak base**. According to the principle of ion trapping, weak bases are ionized in **acidic environments**. Therefore, to increase the renal elimination of Amphetamine, the urine must be **acidified** (e.g., using Ammonium Chloride). Alkalizing the urine would make Amphetamine non-ionized, promoting its reabsorption back into the bloodstream. **2. Why the Other Options are Incorrect:** * **Salicylate (A):** Aspirin is a weak acid. Alkalizing the urine (using Sodium Bicarbonate) converts it into its ionized form, preventing reabsorption and promoting excretion. This is a standard treatment for salicylate poisoning. * **Methotrexate (B):** This is a weak acid. Urinary alkalization is clinically used during high-dose methotrexate therapy to increase its solubility and excretion, preventing crystal-induced nephrotoxicity. * **Phenobarbital (C):** A long-acting barbiturate and a weak acid. Alkalization of urine is a mainstay in managing its toxicity to enhance renal clearance. **High-Yield Clinical Pearls for NEET-PG:** * **Rule of Thumb:** "Like dissolves in like, but opposites ionize." * **Acidic drugs** (Salicylates, Barbiturates, MTX) $\rightarrow$ Excreted in **Alkaline urine**. * **Basic drugs** (Amphetamines, Morphine, Quinine) $\rightarrow$ Excreted in **Acidic urine**. * **Agent for Alkalization:** IV Sodium Bicarbonate ($NaHCO_3$). * **Agent for Acidification:** Ammonium Chloride ($NH_4Cl$) or Vitamin C (though rarely used clinically due to risk of metabolic acidosis).

Question 177: Chloroquine is given in a high loading dose primarily because of which pharmacokinetic property?

A. High volume of distribution (Correct Answer)
B. Poor gastrointestinal absorption
C. High first-pass metabolism
D. All of the above

Explanation: **Explanation:** **1. Why High Volume of Distribution (Vd) is correct:** Chloroquine is a highly lipophilic drug that exhibits extensive tissue binding, particularly in the liver, spleen, kidneys, and melanin-containing tissues (like the retina). This results in an exceptionally high **Volume of Distribution (Vd)**—often exceeding 10,000 L. In pharmacokinetics, the **Loading Dose (LD)** is calculated using the formula: $LD = Vd \times Target\ Plasma\ Concentration$. Since Chloroquine sequesters heavily into tissues, a large initial dose is required to saturate these tissue binding sites and rapidly achieve the therapeutic plasma concentration necessary to exert its antimalarial effect. Without a loading dose, it would take several weeks to reach a steady state. **2. Why other options are incorrect:** * **B. Poor gastrointestinal absorption:** Chloroquine is actually absorbed very rapidly and almost completely (>80%) from the GI tract. Poor absorption would necessitate parenteral administration, not a specific loading dose strategy. * **C. High first-pass metabolism:** Chloroquine does not undergo significant first-pass metabolism; its bioavailability is high. Drugs with high first-pass metabolism (like Nitroglycerin) are usually given via non-oral routes. **3. NEET-PG High-Yield Pearls:** * **Amiodarone and Digoxin** are other classic examples of drugs requiring loading doses due to high Vd and extensive tissue sequestration. * **Chloroquine Toxicity:** Due to its affinity for melanin, long-term use can lead to **"Bull’s eye maculopathy"** (retinopathy). * **Half-life:** Because of its high Vd, Chloroquine has a very long terminal half-life (30–60 days).

Question 178: Monitoring of drug level is not required with which of the following medications?

A. Lithium
B. L-Dopa (Correct Answer)
C. Digoxin
D. Phenytoin

Explanation: **Explanation:** The decision to perform **Therapeutic Drug Monitoring (TDM)** is based on the relationship between a drug’s plasma concentration and its clinical effect or toxicity. **Why L-Dopa is the correct answer:** L-Dopa is used in Parkinson’s disease, where the clinical response (improvement in motor symptoms) is easily observable and measurable at the bedside. TDM is generally **not required** when a drug has a **wide therapeutic index** or when its **pharmacodynamic effect can be easily monitored clinically** (e.g., blood pressure for antihypertensives, INR for warfarin, or motor scales for L-Dopa). **Analysis of Incorrect Options:** TDM is mandatory for the other options because they possess a **narrow therapeutic index**, where the dose required for efficacy is very close to the dose that causes toxicity. * **Lithium (A):** Has a very narrow window (0.6–1.2 mEq/L). Toxicity can lead to severe neurological and renal complications. * **Digoxin (C):** Used in heart failure and atrial fibrillation. Toxicity (arrhythmias, visual halos) occurs at levels slightly above the therapeutic range (0.5–2 ng/mL). * **Phenytoin (D):** Exhibits **zero-order (saturation) kinetics** at therapeutic doses. Small dose increments can lead to disproportionately large increases in plasma levels, causing ataxia and nystagmus. **High-Yield Clinical Pearls for NEET-PG:** * **Indications for TDM:** Narrow therapeutic index, poor correlation between dose and plasma level, non-compliance suspected, or drugs with saturable metabolism. * **Drugs requiring TDM (Mnemonic: "The LiPo DiT"):** **The**ophylline, **Li**thium, **P**henytoin, **D**igoxin, **I**mmunosuppressants (Cyclosporine), **T**ricyclic Antidepressants. * **Exceptions:** TDM is **not** done for drugs whose effects are irreversible (e.g., Aspirin) or easily measured (e.g., L-Dopa, Heparin via aPTT).

Question 179: Which of the following statements regarding zero-order kinetics is true?

A. Half-life is constant.
B. The rate of elimination is dependent on plasma drug concentration.
C. Clearance decreases with an increase in plasma concentration. (Correct Answer)
D. It applies to the majority of drugs.

Explanation: In **Zero-Order Kinetics** (also known as saturation or non-linear kinetics), a constant amount of drug is eliminated per unit time because the elimination processes (like enzymes or transporters) are saturated [1], [2]. **Why Option C is Correct:** Clearance (CL) is defined by the formula: **CL = Rate of Elimination / Plasma Concentration**. In zero-order kinetics, the *Rate of Elimination* is constant (fixed). Therefore, as the *Plasma Concentration* increases, the denominator in the formula grows while the numerator remains the same. This results in a mathematical and physiological **decrease in clearance** as drug levels rise [1]. **Analysis of Incorrect Options:** * **Option A:** In zero-order kinetics, **half-life is not constant**; it increases as the plasma concentration increases (the more drug you have, the longer it takes to clear half of it because the exit gate is fixed). * **Option B:** The rate of elimination is **independent** of plasma concentration [1]. It remains constant regardless of how much drug is in the body [2]. * **Option D:** Most drugs follow **First-Order Kinetics** (where a constant *fraction* is eliminated) [2]. Zero-order is rare and usually occurs at high/toxic doses. **NEET-PG High-Yield Pearls:** * **Mnemonic for Zero-Order Drugs:** **"WATT"** – **W**arfarin (at high doses), **A**lcohol (Ethanol), **T**heophylline, **T**olbutamide, and **Phenytoin** (most common exam example) [1]. * **First-order kinetics:** Half-life and Clearance are **constant**. * **Zero-order kinetics:** Rate of elimination is **constant** [2]. * Zero-order kinetics are also called **Capacity-limited elimination** or **Michaelis-Menten kinetics** [1].

Question 180: Which of the following drugs has high plasma protein binding to serum albumin?

A. Lignocaine
B. Warfarin (Correct Answer)
C. Quinidine
D. All of the above

Explanation: ### Explanation **1. Why Warfarin is Correct:** The binding of drugs to plasma proteins is primarily determined by their chemical nature. **Acidic drugs** [2] (like Warfarin [1], NSAIDs, Sulfonamides, and Phenytoin) bind predominantly to **Serum Albumin**. Warfarin is highly protein-bound (>99%) [1]. This is clinically significant because only the "free" fraction of the drug is pharmacologically active [3]. Drugs with high albumin binding are prone to displacement interactions; for example, if another drug displaces Warfarin from albumin, it can lead to a sudden increase in free Warfarin levels, resulting in hemorrhage. **2. Why Other Options are Incorrect:** * **Lignocaine & Quinidine:** These are **basic drugs**. Basic drugs do not primarily bind to albumin; instead, they bind to **$\alpha_1$-acid glycoprotein (AAG)** [4]. * **All of the above:** This is incorrect because the question specifically asks for binding to *serum albumin*, which is selective for acidic drugs. **3. High-Yield NEET-PG Pearls:** * **Albumin vs. AAG:** Remember the mnemonic: **"A for A"** (Acidic drugs bind to Albumin) and **"B for B"** (Basic drugs bind to $\alpha_1$-acid glycoprotein/Beta-globulin). * **Clinical Impact:** High protein binding usually results in a **low Volume of Distribution ($V_d$)** because the drug is sequestered within the vascular compartment. * **Disease States:** In **Hypoalbuminemia** (e.g., Nephrotic syndrome, Cirrhosis), the dose of highly protein-bound drugs like Warfarin or Phenytoin must be reduced to avoid toxicity [2]. * **AAG Levels:** $\alpha_1$-acid glycoprotein is an acute-phase reactant; its levels increase during inflammation, surgery, or trauma, potentially decreasing the free fraction of basic drugs like Lignocaine [4].

Practice by Chapter

Absorption and Bioavailability

Practice Questions

Drug Distribution and Protein Binding

Practice Questions

Biotransformation and Metabolism Pathways

Practice Questions

Renal and Non-renal Excretion

Practice Questions

Compartment Models

Practice Questions

Dose-Response Relationships

Practice Questions

Drug Efficacy and Potency

Practice Questions

Drug Tolerance and Tachyphylaxis

Practice Questions

Population Pharmacokinetics

Practice Questions

Pharmacokinetic Variability

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free